Alnylam Pharmaceuticals
(ALNY)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2004 | 03-2004 | 12-2003 | 09-2003 | 06-2003 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -20,538 | -13,582 | N/A | -16,498 | -5,394 |
| Depreciation Amortization | 965 | 511 | N/A | 404 | 124 |
| Accounts receivable | -3,000 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 294 | 2,126 | N/A | 349 | 670 |
| Other Working Capital | 2,466 | 2,365 | 1,331 | -165 | 988 |
| Other Operating Activity | 4,871 | 86 | 8,461 | 5,439 | 154 |
| Operating Cash Flow | $-14,942 | $-8,494 | $9,792 | $-10,471 | $-3,458 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -14,207 | N/A | N/A | N/A | N/A |
| PPE Investments | -6,371 | -2,072 | N/A | -1,444 | -1,023 |
| Net Acquisitions | N/A | N/A | N/A | -121 | N/A |
| Investing Cash Flow | $-20,578 | $-2,072 | $N/A | $-1,565 | $-1,023 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 5,705 | 1,879 | N/A | 1,369 | 589 |
| Debt Repayment | -1,859 | -1,859 | N/A | -3,118 | -79 |
| Common Stock Issued | 30,100 | 114 | N/A | 7 | 7 |
| Other Financing Activity | 10,326 | 8,858 | 0 | 24,792 | -615 |
| Financing Cash Flow | $44,272 | $8,992 | $N/A | $23,050 | $-98 |
| Exchange Rate Effect | -54 | -7 | N/A | -3 | N/A |
| Beginning Cash Position | 23,193 | 23,193 | N/A | 15,477 | 15,477 |
| End Cash Position | 31,891 | 21,612 | N/A | 26,488 | 10,898 |
| Net Cash Flow | $8,698 | $-1,581 | $9,792 | $11,011 | $-4,579 |
| Free Cash Flow | |||||
| Operating Cash Flow | -14,942 | -8,494 | 9,792 | -10,471 | -3,458 |
| Capital Expenditure | -6,438 | -2,139 | N/A | -1,444 | -1,023 |
| Free Cash Flow | -21,380 | -10,633 | 9,792 | -11,915 | -4,481 |